March 26, 2021
Medical robot company CUREXO has announced that its in-house developed artificial joint surgical robot, CUVIS-joint, has received the CE Mark from the European Economic Area (EEA). The South Korean-based company said the robot was MFDS certified in June 2020 and has been provided to domestic general hospitals and orthopedic hospitals.
In early March 2021, Sakra World Hospital in India carried out 100 successful total knee replacement surgeries with the Meril-CUVIS joint robotics system, and is carrying out about 10 operations per week, the company said. With the CE marking, CUREXO plans to expand its market across Europe, Australia, and parts of Asia. The company said it will also obtain FDA approval to further expand globally.
“We are happy to see that we were approved for the CE marking earlier than we expected,” said Jaejun Lee, CEO of CUREXO. “We anticipated approval to take place in the second quarter of the year. We plan on promoting partnerships with implant and medical enterprises in Europe and proceed to signing agreements. Also, we expect a positive outcome for our expansion into the global market in 2021 with our early approval.”
CUREXO began developing full-fledged medical robots after it was acquired by Korea Yakult Co. Ltd. in 2011. By taking over the medical robot business division of Hyundai Heavy Industries in 2017, CUREXO has secured a portfolio that includes CUVIS-joint, CUVIS-spine and “Morning Walk, a walking rehabilitation robot. More details on the company can be found here.